FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Disagreements Continue on Separate Biosimilar User Fees

[ Price : $8.95]

The Generic Pharmaceutical Association disagrees with FDA, PhRMA, and BIO on the need for a separate biosimilars user fee program.

CDER Reviewers' Thumbs Down for Xarelto

[ Price : $8.95]

CDER drug reviewers recommend not to approve a Janssen Pharmaceuticals NDA for its investigational drug Xarelto (rivaroxaban), whi...

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Creations Garden Natural Products, Edelweiss Farms, Facet Technologies, Lehigh V...

Offshore Drug Plants Riskier Than U.S. Facilities: Study

[ Price : $8.95]

Ohio State University researchers say they found a higher risk of drug manufacturing quality problems in Puerto Rican facilities o...

Address Corrected in Mobile Medical Apps Notice

[ Price : $8.95]

Federal Register Notice: FDA corrects an address in an 8/12 Federal Register notice announcing a workshop on a mobile medical appl...

Leo Asks Dovonex ANDA Restrictions

[ Price : $8.95]

Leo Pharma asks FDA to require applicants for generic Dovonex to perform specific tests before their ANDA can be approved.

New Medical Device Reviewer Training Programs Out

[ Price : $8.95]

FDA announces two new staff training programs for medical device reviewers that it says will improve their consistency.

Gardasil Vaccine Samples Contaminated: SANE Vax

[ Price : $8.95]

Patient activist group SANE Vax asks FDA to investigate the presence of HPV recombinant DNA that it says is contaminating Mercks G...

Info on Dispute Resolution Sent to OMB

[ Price : $8.95]

Federal Register Notice: FDA submits a proposed collection of information on a guidance on formal dispute resolution to the Office...